G Cserni
Overview
Explore the profile of G Cserni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
665
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cserni G, Ambrozay E, Serenyi P, Bori R, Sejben I, Csorgo E, et al.
Eur J Surg Oncol
. 2021 Dec;
48(4):742-747.
PMID: 34872778
Introduction: - At present, surgical strategies for breast cancer patients with >2 lymph nodes (LN) involved differ from those with no or lower degree of nodal involvement. Preoperative assessment of...
2.
Savolt A, Cserni G, Lazar G, Maraz R, Kelemen P, Kovacs E, et al.
Eur J Surg Oncol
. 2019 May;
45(10):1835-1838.
PMID: 31126680
Introduction: Ipsilateral breast recurrence or second primary breast cancer can develop in patients who have undergone breast conserving surgery (BCS) and axillary surgery. The purpose of this study was to...
3.
Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms K, Neff C, et al.
Ann Oncol
. 2019 Apr;
30(8):1406.
PMID: 30929001
No abstract available.
4.
Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms K, Neff C, et al.
Ann Oncol
. 2018 Jun;
29(9):1948-1954.
PMID: 29917049
Background: Based on its mechanism of action, PARP inhibitor therapy is expected to benefit mainly tumor cases with homologous recombination deficiency (HRD). Therefore, identification of tumor types with increased HRD...
5.
Cserni G, Charafe-Jauffret E, van Diest P
Eur J Surg Oncol
. 2018 May;
44(8):1128-1134.
PMID: 29706301
Inflammatory breast cancer (IBC) is a clinico-pathological entity, which has specific features of inflammation and pathological evidence of cancer, most often involving dermal lymphatics. This review looks at IBC from...
6.
Foschini M, Miglio R, Quinn C, Belgio B, Regitnig P, Bianchi S, et al.
Eur J Surg Oncol
. 2017 Jun;
43(8):1421-1427.
PMID: 28576464
Aim: The aim of the present study was to evaluate the risk of axillary non-sentinel lymph-node metastases (ALN) in breast cancer patients presenting macrometastasis (Mac-m) in the sentinel lymph node...
7.
Cserni G, Wells C, Kaya H, Regitnig P, Sapino A, Floris G, et al.
Virchows Arch
. 2016 Jan;
468(4):473-81.
PMID: 26818833
Microinvasion is the smallest morphologically identifiable stage of invasion. Its presence and distinction from in situ carcinoma may have therapeutic implications, and clinical staging also requires the recognition of this...
8.
Balmativola D, Marchio C, Maule M, Chiusa L, Annaratone L, Maletta F, et al.
Breast Cancer Res Treat
. 2014 Nov;
148(3):511-23.
PMID: 25395316
To identify markers of non-response to neoadjuvant chemotherapy (NAC) that could be used in the adjuvant setting. Sixteen pathologists of the European Working Group for Breast Screening Pathology reviewed the...
9.
Meretoja T, Heikkila P, Mansfield A, Cserni G, Ambrozay E, Boross G, et al.
Ann Surg Oncol
. 2014 Mar;
21(7):2229-36.
PMID: 24664623
Background: Sentinel node biopsy (SNB) is the "gold standard" in axillary staging in clinically node-negative breast cancer patients. However, axillary treatment is undergoing a paradigm shift and studies are being...
10.
Maraz R, Boross G, Pap-Szekeres J, Rajtar M, Ambrozay E, Cserni G
Pathol Oncol Res
. 2013 Aug;
20(1):169-77.
PMID: 23934505
Axillary sentinel node (A-SN) biopsy is a standard procedure in breast cancer surgery. Sampling of intenal mammary sentinel nodes (IM-SN) is not performed routinly, although it is also considered an...